| Product NDC: | 59630-659 |
| Proprietary Name: | Kapvay |
| Non Proprietary Name: | clonidine hydrochloride |
| Active Ingredient(s): | .2 mg/1 & nbsp; clonidine hydrochloride |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, EXTENDED RELEASE |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 59630-659 |
| Labeler Name: | Shionogi Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA022331 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20101209 |
| Package NDC: | 59630-659-08 |
| Package Description: | 6 BOTTLE in 1 TRAY (59630-659-08) > 8 TABLET, EXTENDED RELEASE in 1 BOTTLE |
| NDC Code | 59630-659-08 |
| Proprietary Name | Kapvay |
| Package Description | 6 BOTTLE in 1 TRAY (59630-659-08) > 8 TABLET, EXTENDED RELEASE in 1 BOTTLE |
| Product NDC | 59630-659 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | clonidine hydrochloride |
| Dosage Form Name | TABLET, EXTENDED RELEASE |
| Route Name | ORAL |
| Start Marketing Date | 20101209 |
| Marketing Category Name | NDA |
| Labeler Name | Shionogi Inc. |
| Substance Name | CLONIDINE HYDROCHLORIDE |
| Strength Number | .2 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Adrenergic alpha2-Agonists [MoA],Central alpha-2 Adrenergic Agonist [EPC] |